Strategic funding With $225M in funding and recent ATM financing of $50M, Inhibikase is well-capitalized to advance its Phase 3 PAH program (IKT-001). This financial runway supports potential partnerships or licensing discussions around late-stage development, manufacturing scale-up, and global regulatory strategies.

PAH focus The company exclusively targets Pulmonary Arterial Hypertension with a gut-masked imatinib prodrug (IKT-001). This specialization presents opportunities to engage in translational medicine collaborations, patient access initiatives, and payer discussions centered on orphan PAH therapies.

Key leadership Recent leadership appointments including a new CEO, CFO, and Chief Commercial and Strategy Officer signal a strategic shift toward commercial readiness and value realization, creating openings for partnerships in market access, pricing strategy, and commercial planning.

Clinical momentum Initiation of the IMPROVE-PAH Phase 3 study and prior non-human primate safety and bioequivalence work indicate progress toward potential regulatory submissions. This progress invites opportunities for contract research, CRO partnerships, and advisory roles to accelerate development timelines.

Market positioning Imatinib-based PAH program with orphan indication and sizable peak sales potential positions Inhibikase as an attractive partner for stylized commercial collaborations, distribution agreements, and co-development discussions with specialty pharma players and CROs serving rare cardiovascular conditions.